Last reviewed · How we verify
NCT03756116
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
NA trial testing Epinephrine sprayed on the papilla in Post-ERCP Acute Pancreatitis in 2,000 participants. Status unknown.
1 October 2020
Quick facts
| Lead sponsor | The Second Hospital of Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 2,000 |
| Start date | 1 October 2018 |
| Primary completion | 1 October 2020 |
| Estimated completion | 1 October 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Epinephrine sprayed on the papilla
- Saline sprayed on the papilla
Conditions studied
- Post-ERCP Acute Pancreatitis — all drugs for Post-ERCP Acute Pancreatitis →
- Epinephrine — all drugs for Epinephrine →
Sponsor
The Second Hospital of Nanjing Medical University
Who can join
Adults 18 to 80, any sex, with Post-ERCP Acute Pancreatitis or Epinephrine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication with high costs, significant morbidity and even mortality. The major mechanisms of PEP is the papillary edema which is caused by manipulations during cannulation or endoscopic treatment. The papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. Nitroglycerin can reduce the Oddis sphincter tension, the internal pressure of the biliary tract and the pancreatic duct. Therefore, it is widely used in clinical to prevent and treat pancreatitis. Many studies found nitroglycerin might be effective in preventing PEP. And topical application of epinephrine on the papilla may reduce papillary edema by decreasing capillary permeability or by relaxing the sphincter of Oddi. There are reports that epinephrine sprayed on the papilla may be effective to prevent PEP. The investigators therefore designed a prospective randomized trial to determine whether routine using papillary epinephrine spraying in patients received octreotide can reduce post-ERCP pancreatitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03756116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-ERCP Acute Pancreatitis
Currently open trials in the same condition.
- NCT07117318 — Rectal NSAIDs With/Without PD Stent for PEP Prevention · NA · recruiting
- NCT06260878 — Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis · Phase 4 · recruiting
- NCT05267379 — An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreati · recruiting
Other The Second Hospital of Nanjing Medical University trials
Trials by the same sponsor.
- NCT07331688 — CMTS0515-auWMT for Radiation Enteritis · Phase 1, PHASE2 · active not recruiting
- NCT06839586 — CMTS4520 for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · active not recruiting
- NCT06839599 — CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · not yet recruiting
- NCT06844708 — CMTS0929 for Inflammatory Bowel Disease · EARLY_PHASE1 · not yet recruiting
- NCT06836427 — CMTS0929 for Clostridioides Difficile Infection · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03756116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Nanjing Medical University
- Last refreshed: 28 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03756116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing